ArticleJournal of medicinal chemistry2026
Intracellular Activation of Dual-Pharmacophore Artezomib Enhances Selective Cytotoxicity in Hematologic Malignancies.
Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
We describe DQ-9, a dual-pharmacophore artezomib analogue that combines selective inhibition of immunoproteasome β5i with iron-dependent activation of artemisinin. DQ-9 exploits the elevated labile iron pool characteristic of hematologic malignancies, yielding selective cytotoxicity toward leukemia and multiple myeloma cells. DQ-9 affords sustained proteasome inhibition and induces oxidative stress and apoptosis through its iron-mediated activation and subsequent intracellular conversion to additional inhibitory species. In contrast, the deoxy analogue DQ-10, which lacks this activatable component, displays activity attributable solely to β5i inhibition, with correspondingly reduced cytotoxic potency. These findings establish iron-activable, β5i-targeting hybrids as a promising strategy to achieve enhanced selectivity and therapeutic efficacy against hematological malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.